01—Abstract
Summary
Summary of the 8-K filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.
CVS Health reported first-quarter 2025 results on May 1, 2025, with total revenues up 7.0% to $94.6 billiona, GAAP diluted EPS of $1.41 (up from $0.88), and Adjusted EPS of $2.25 (up from $1.31).
The beat was driven mainly by Health Care Benefits, where the medical benefit ratio improved 310 basis points to 87.3%, helped by $1.65 billionb of favorable prior-year reserve development and better Medicare performance, including improved Medicare Advantage star ratings for 2025. Adjusted operating income rose 54.9% to $4.6 billion, with gains in all three operating segments. GAAP operating income rose 48.6% to $3.4 billion, but was reduced by a $387 million Omnicare False Claims Act jury verdict charge and a $247 million loss on the wind-down and sale of Accountable Care assets.
Management raised its 2025 Adjusted EPS guidance to $6.00c-$6.20 (from $5.75-$6.00) and its operating cash flow guidance to about $7.0 billion (from about $6.5 billion). It cut GAAP diluted EPS guidance to $4.23-$4.43 (from $4.58-$4.83), reflecting the Omnicare charge and other non-GAAP items. Management said it remains cautious for the rest of the year because of elevated medical cost trends and possible macro headwinds.
The company also announced it will exit the individual ACA exchange business for 2026, and it recorded a $448 milliond premium deficiency reserve in that line for 2025. For investors, the quarter shows strong underlying Health Care Benefits performance, but much of the upside came from prior-year reserve releases that do not recur, and the GAAP-to-adjusted gap is widening. Investors will likely focus on whether medical cost trends hold, how durable Medicare margins are, and the financial impact of the Omnicare verdict, which the company plans to appeal.
02—Key points
Key Highlights
- Total revenues rose 7.0% to $94.6B, with growth in all segments; Health Care Benefits revenue rose 8.0% and Pharmacy & Consumer Wellness revenue rose 11.1%.
- Adjusted EPS of $2.25 beat the prior-year $1.31 by 72%; GAAP diluted EPS was $1.41 versus $0.88.
- Medical benefit ratio improved 310 bps to 87.3%, helped by $1.65B of favorable prior-year health care cost development, though this does not recur in the same way.
- Adjusted operating income rose 54.9% to $4.58B, with Health Care Benefits up $1.26B to $1.99B, Health Services up 17.6% to $1.60B, and Pharmacy & Consumer Wellness up 11.6% to $1.31B.
- 2025 Adjusted EPS guidance raised to $6.00-$6.20 and operating cash flow guidance raised to about $7.0B, while GAAP EPS guidance was cut to $4.23-$4.43 due to the Omnicare charge.
- $387M Omnicare False Claims Act jury verdict charge and $247M loss on the Accountable Care asset wind-down/sale weighed on GAAP results; the judgment is not final and the company intends to appeal.
- CVS will exit the individual ACA exchange business after 2025, and a $448M premium deficiency reserve was recorded for 2025 exchange losses.
03—Questions
Frequently Asked Questions
Why did CVS raise Adjusted EPS guidance but lower GAAP EPS guidance?
The GAAP guidance cut mainly reflects the $387 million Omnicare litigation charge and the $247 million loss on Accountable Care assets, which are excluded from Adjusted EPS. Adjusted EPS was raised because underlying operating performance, especially in Health Care Benefits and Health Services, was stronger than expected.
How much of the Health Care Benefits improvement came from one-time or non-recurring items?
A significant part did. The company reported $1.65 billion of favorable prior-year health care cost development, plus improved Medicare performance and better star ratings for 2025. The prior-year development is not a repeatable source of earnings in the same way, so the underlying margin trend matters more for future quarters.
What is the financial impact of the Omnicare verdict and what happens next?
The jury found Omnicare and CVS liable under the federal False Claims Act for dispensing practices from 2010 to 2018, though damages were assessed only against Omnicare. The company recorded a $387 million pre-tax charge. The judgment is not final until the court enters penalties, and CVS plans to appeal once it is entered, so the final amount could change.
Why is CVS exiting the individual ACA exchange business?
Management said the decision is part of a broader effort to focus its portfolio. It recorded a $448 million premium deficiency reserve for anticipated 2025 exchange losses, and Aetna will independently run ACA plans for 2026. CVS will serve existing exchange members through 2025 and handle residual activities in 2026.
Is CVS's cash flow outlook improving?
Operating cash flow guidance was raised to about $7.0 billion from about $6.5 billion. First-quarter operating cash flow was $4.6 billion, slightly below the $4.9 billion in the prior-year quarter, so the full-year raise depends on cash generation in the remaining quarters.
04—Continue